entertainment -WSS

entertainment

author：entertainment 2025-09-09 19:29:11 - browse：38569

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： The Readout: Lenmeldy, GLP

leisure time

WSS

Oprah kicked off a national conversation on obesity. Let's have it

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Food as medicine: Medically tailored meals may get standardized

As digital health tech proliferates, a new institute aims to cut through hype

Google and Epic fight stronger regulation of AI in health care

Group opposing PBM reform sets lobbying record

leisure time

entertainment

entertainment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Dobbs anniversary: the lost opportunity of abortion as health care

Primary care physicians play key roles in Alzheimer's management

The cancer drug shortage isn’t new — and neither are the solutions

STAT Virtual Event: The State of Biosimilars: What to Watch

Psychedelics group wrestles with new pharma identity

Primary care physicians play key roles in Alzheimer's management

State Dept. review finds Biden bears some blame for Afghanistan failures

Biden tests positive for Covid

focus

Sanders adds drug shortage policies to pandemic preparedness bill

Google and Epic fight stronger regulation of AI in health care

FDA approves RSV monoclonal antibody for infants, toddlers

Google and Epic fight stronger regulation of AI in health care

In early work, researchers turn to CRISPR to treat Alzheimer's

Key House panel plots a new health care package

focus

leisure time

leisure time

knowledge